NCT05025631View on ClinicalTrials.gov

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Colorectal Cancer
Interventions
DRUG

Fruquintinib

Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.

Trial Locations (1)

610000

China West Hospital, Chengdu

All Listed Sponsors
lead

Zhen-Yu Ding

OTHER

NCT05025631 - A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） | Biotech Hunter | Biotech Hunter